, Tracking Stock Market Picks
Enter Symbol:
Sarepta Therapeutics Inc (SRPT) [hlAlert]

up 7.37 %

Sarepta Therapeutics Inc (SRPT) rated Buy with price target $50 by ROTH Capital

Posted on: Wednesday,  Aug 26, 2015  8:25 AM ET by Roth Capital

Roth Capital rated Buy Sarepta Therapeutics Inc (NASDAQ: SRPT) on 08/26/2015, when the stock price was $33.74. Since
then, Sarepta Therapeutics Inc has gained 7.38% as of 01/19/2016's recent price of $36.23.
If you would have followed this Roth Capital's recommendation on SRPT, you would have gained 7.37% of your investment in 146 days.

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/26/2015 8:25 AM Buy
33.74 50.00
as of 8/27/2015
1 Week up  7.37 %
1 Month   
3 Months   
1 YTD up  7.37 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy